IMNN — Imunon, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 749647 ·
Last close
$0.61
Market Cap
$3.97M
52W High
$4.35
52W Low
$0.50
ADV30
187,418
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -3,447,701 | -3,750,287 | 12,008,678 | 4,039,298 | 9,386,352 |
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -4,306,552 | -4,249,022 | 8,018,713 | 4,794,070 | 4,659,082 |
| Dec 2025 | 0 | — | -4,261,703 | -4,222,850 | 12,288,116 | 8,781,059 | 5,226,240 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,870,802
Investing CF
$-74,461
Financing CF
$17,773,100
CapEx
$-282,364
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-3.18
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-432,111,495
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-14,791,250
Pretax Income TTM
$-15,036,273
Interest Exp TTM
$341,406
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -14,650,694 | -14,495,028 | 12,288,116 | 5,226,240 | 7,061,876 | -13,896,624 |
| Dec 2024 | 0 | -19,132,446 | -18,620,242 | 9,717,364 | 5,473,066 | 4,244,298 | -18,854,970 |
| Dec 2023 | 0 | -21,030,430 | -19,514,977 | 21,918,069 | 8,530,427 | 13,387,642 | -19,022,148 |
| Dec 2022 | 500,000 | -24,921,565 | -35,898,234 | 43,975,894 | 14,648,028 | 29,327,866 | -23,096,895 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-14,715,110
OpCashFlow TTM
—
Assets (Latest)
$14,989,113
Forward EPS
$-1.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XTLB | XTL BIOPHARMACEUTICALS LTD | $3.98M | $1.62 | — |
| SILO | Silo Pharma, Inc. | $4.00M | $1.71 | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $4.02M | $0.31 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $4.11M | $0.93 | — |
| SXTC | China SXT Pharmaceuticals, Inc. | $3.78M | $2.86 | — |
News headlines (Yahoo Finance, 1h cache)
Imunon, Inc. Q3 2026 Earnings Call Summary
2026-11-13 01:44 · Yahoo
Imunon (IMNN) Q3 2026 Earnings Call Transcript
2026-11-12 23:00 · Yahoo
IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 13:00 · Yahoo
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
2026-11-06 14:00 · Yahoo
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
2026-11-02 13:30 · Yahoo
IMUNON Announces Strategic Sale of ThermoDox®
2026-10-21 12:15 · Yahoo
IMUNON to Participate in Upcoming Investor Conferences
2026-10-08 13:00 · Yahoo
IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer
2026-10-01 15:40 · Yahoo
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
2026-09-24 12:05 · Yahoo
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
2026-09-22 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.